Last updated: July 31, 2026
Bethanechol chloride is an old, low-cost muscarinic agonist used primarily for postoperative urinary retention and neurogenic bladder. It has no meaningful remaining composition-of-matter exclusivity, no FDA-recognized regulatory exclusivity, and no visible late-stage clinical development program. Commercial demand is fragmented across generic tablets and compounded or specialty formulations. The market is likely to remain stable to modestly declining in revenue, with periodic supply disruptions creating more commercial risk than patent expiry.
What is the current FDA status of bethanechol chloride?
Bethanechol chloride is an FDA-approved prescription cholinergic agent. The drug directly stimulates muscarinic receptors and increases detrusor muscle tone, supporting bladder emptying in selected patients with nonobstructive urinary retention.
The principal labeled uses are:
- Postoperative and postpartum nonobstructive urinary retention
- Neurogenic bladder atony
- Urinary retention associated with certain neurologic conditions
Bethanechol is available primarily as oral tablets in 5 mg, 10 mg, 25 mg, and 50 mg strengths. Product availability varies by manufacturer and wholesaler. DailyMed listings identify multiple generic bethanechol chloride products, while the historical Urecholine brand has largely exited routine commercial distribution.[1]
Bethanechol is not a modern first-line therapy for most lower urinary tract disorders. Catheterization, alpha blockers, bladder training, treatment of obstruction, and management of underlying neurologic disease are often preferred depending on the cause of retention.
What is the FDA regulatory pathway for bethanechol?
Bethanechol entered the market decades ago through the conventional new-drug approval framework. Current commercial products are generally marketed through abbreviated new drug applications or legacy approvals rather than through new clinical development programs.
The FDA regulatory profile is characterized by:
| Regulatory category |
Bethanechol chloride status |
| Active ingredient |
Established small molecule |
| Primary route |
Oral tablet |
| FDA approval |
Yes |
| Generic competition |
Yes |
| Orphan-drug exclusivity |
None identified |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
None identified |
| Priority review |
Not applicable |
| Biosimilar pathway |
Not applicable |
| Current pivotal development program |
None identified |
Bethanechol is a small-molecule generic drug, not a biologic. Biosimilar competition is therefore irrelevant. Competitive pressure comes from generic manufacturers, therapeutic substitution, compounded products, catheter-based management, and alternative medicines.
What clinical trials are evaluating bethanechol chloride?
The current clinical-trial profile is limited. Bethanechol does not have a visible Phase 2 or Phase 3 development program comparable with newer urology, gastroenterology, or autonomic-disorder medicines. Historical studies evaluated its effects on bladder contractility, postoperative urinary retention, reflux, and gastrointestinal motility, but those studies generally predate modern trial-registration practices.
A ClinicalTrials.gov review does not indicate an active registration-driven program likely to generate a new FDA label expansion or materially change the commercial market.[2]
Which clinical uses have the strongest evidence?
The most defensible clinical use remains bladder atony or nonobstructive urinary retention. Even in that setting, evidence is limited by old study designs, small sample sizes, heterogeneous patient populations, and the difficulty of separating pharmacologic benefit from spontaneous recovery after surgery or resolution of the underlying cause.
| Clinical area |
Development status |
Commercial implication |
| Postoperative urinary retention |
Historical clinical use; no modern pivotal program |
Maintains low-volume hospital and outpatient demand |
| Neurogenic bladder atony |
Established labeled use |
Niche demand in urology and rehabilitation |
| Gastrointestinal motility |
Historical or off-label use |
Limited commercial contribution |
| Gastroesophageal reflux |
Historical investigation; not a core modern indication |
Minimal current value |
| Pediatric urinary disorders |
Specialist use in selected cases |
Small, formulation-sensitive segment |
| Central autonomic disorders |
No meaningful modern development program |
No near-term market expansion |
Bethanechol has a narrow therapeutic margin. Cholinergic adverse effects can include abdominal cramps, diarrhea, sweating, salivation, bronchospasm, bradycardia, hypotension, and urinary urgency. Contraindications and warnings include asthma, peptic ulcer disease, bradycardia, hypotension, hyperthyroidism, epilepsy, and mechanical urinary or gastrointestinal obstruction.[3]
Are there active clinical trials or label-expansion opportunities?
No active late-stage program is apparent for bethanechol chloride. Potential research areas exist in neurogenic bladder, postoperative urinary retention, and autonomic dysfunction, but the commercial rationale is weak because:
- The active ingredient is generic.
- Clinical endpoints can be difficult to standardize.
- Competing management approaches are inexpensive.
- A new indication would face limited reimbursement upside.
- A reformulated product would need to differentiate on adherence, tolerability, or delivery.
A sponsor could pursue a 505(b)(2) strategy for a new dosage form, sustained-release product, pediatric liquid, or combination therapy. That route could create regulatory differentiation, but it would require new clinical and commercial investment in a market with limited revenue potential.
How large is the bethanechol chloride market?
Public market reports frequently combine bethanechol with broader urinary-retention, cholinergic, or generic urology categories. Those estimates are not reliable measures of bethanechol-specific sales. The product is generally too small and fragmented to have a consistently disclosed global revenue figure.
A practical market assessment places bethanechol in the low-value generic segment:
| Market characteristic |
Assessment |
| Revenue scale |
Small, likely low-single-digit millions of dollars globally on a product-only basis |
| Volume concentration |
Generic oral tablets |
| Geographic concentration |
United States, selected European markets, Japan, India, and other regulated generic markets |
| Prescriber base |
Urologists, hospital physicians, rehabilitation specialists, selected neurologists |
| Payer sensitivity |
High |
| Brand pricing power |
None or minimal |
| Supply-chain sensitivity |
High relative to market size |
| Growth driver |
Periodic shortages, new generic entrants, specialty formulations |
| Primary risk |
Discontinuation, low manufacturing margins, therapeutic substitution |
The largest commercial uncertainty is not demand creation. It is manufacturer participation. A low-volume product may remain clinically important while becoming unattractive to manufacturers because of active pharmaceutical ingredient costs, batch-size inefficiency, quality-system requirements, and limited reimbursement.
What is the projected bethanechol chloride market through 2030?
The base case is a flat-to-declining revenue market through 2030, with unit demand broadly stable and nominal revenue affected by generic price changes and supply events.
| Scenario |
2025-2030 volume trend |
2025-2030 revenue trend |
Main assumptions |
| Base case |
0% to 2% annual decline |
Flat to 2% annual decline |
Stable clinical use, generic pricing, no major new formulation |
| Upside case |
1% to 3% annual growth |
2% to 5% annual growth |
Persistent shortages, expanded specialty use, pediatric or liquid formulation |
| Downside case |
3% to 7% annual decline |
5% to 10% annual decline |
Manufacturer exits, substitution with catheterization or other therapies |
The base-case market remains commercially small. A new formulation could increase revenue per prescription without substantially increasing treated-patient volume. The most plausible value-creation opportunity is a reliable supply platform rather than a conventional branded launch.
What patents protect bethanechol chloride?
Bethanechol chloride has no meaningful remaining patent barrier around the active pharmaceutical ingredient. The core molecule and conventional oral-tablet concept are old. Any historic composition-of-matter, formulation, or use patents associated with the original product have expired.
How many patents cover bethanechol chloride?
The number of historical records that mention bethanechol may be substantial, but the number of enforceable patents blocking ordinary generic tablets is effectively zero. Patent documents may still appear in databases because they relate to:
- Broad muscarinic agonist classes
- Combination products
- Drug-delivery platforms
- Methods for treating urinary or gastrointestinal disorders
- Manufacturing processes
- Compounded or liquid formulations
A patent that lists bethanechol in a broad Markush claim does not necessarily create a practical barrier to a standard generic tablet. Freedom-to-operate analysis must examine claim scope, expiration, prosecution history, jurisdiction, and whether the commercial product practices the claims.
| Patent category |
Current risk to conventional bethanechol tablets |
| Active-ingredient patent |
Negligible |
| Original product patent |
Expired |
| Standard tablet formulation |
Negligible |
| Sustained-release formulation |
Potentially relevant only if an active claim exists |
| Liquid or pediatric formulation |
Product-specific risk |
| Combination therapy |
Product-specific risk |
| Manufacturing process |
Possible, but usually avoidable through alternate processes |
| Method of use |
Low unless tied to a narrowly claimed new indication |
What is the Orange Book status of bethanechol chloride?
Bethanechol products may appear in FDA approval and Orange Book records through historical brand and generic entries, but the relevant commercial question is whether any listed patent or regulatory exclusivity blocks an ANDA applicant. For conventional bethanechol chloride tablets, no active Orange Book patent estate is expected to create a meaningful generic-entry barrier.[4]
The Urecholine brand was marketed by Merck historically. Its commercial discontinuation does not restore exclusivity or prevent generic supply. Generic applicants can rely on the FDA-approved labeling and established safety profile, subject to ordinary ANDA requirements.
Are there Paragraph IV challenges involving bethanechol chloride?
Bethanechol chloride is unlikely to generate material current Paragraph IV litigation. Paragraph IV certifications are most commercially significant when a listed patent remains active and the reference product has meaningful sales. Bethanechol lacks both characteristics.
A generic applicant could file a Paragraph IV certification if an applicable listed patent were identified. The expected litigation risk for a conventional tablet would remain low because:
- The active ingredient is longstanding.
- The reference product has limited commercial value.
- No major patent settlement economics are apparent.
- Multiple generic and nonpatent alternatives exist.
- The likely damages base is small.
There is no known strategic patent settlement framework comparable with those associated with high-revenue branded medicines.
What patent litigation affects bethanechol chloride?
No material current patent litigation is apparent involving the conventional bethanechol chloride tablet market. Litigation risk is more likely to arise from product-quality claims, manufacturing disputes, supply contracts, or formulation-specific patents than from the underlying molecule.
A company launching a new oral liquid, modified-release product, transdermal system, or combination therapy would face a different risk profile. Those products could attract patents directed to excipients, release profiles, dosing schedules, stability, or administration devices.
Which companies manufacture or compete with bethanechol chloride?
The competitive field is fragmented. Generic manufacturers and contract suppliers may enter or leave the market based on procurement economics. Availability can differ by dose strength and country.
The main competitive groups are:
- Generic tablet manufacturers selling under their own labels.
- Specialty pharmacies preparing capsules or liquids when commercial tablets are unavailable.
- Hospital pharmacies managing short-term postoperative retention.
- Suppliers of catheter products and bladder-management systems.
- Alternative pharmacologic treatments directed at the underlying urologic condition.
Bethanechol does not compete primarily against another branded cholinergic agonist. Its practical competition is often procedural management, particularly intermittent catheterization, and treatment of obstruction or neurologic disease.
How does bethanechol compare with alternative urinary-retention treatments?
| Treatment |
Primary role |
Advantage over bethanechol |
Limitation |
| Intermittent catheterization |
Direct bladder emptying |
Reliable immediate decompression |
Burden, infection risk, training |
| Indwelling catheter |
Acute or persistent retention |
Rapid and dependable |
Infection and device complications |
| Alpha blocker |
Functional outlet obstruction |
Better fit for selected obstructive causes |
Not useful for all retention mechanisms |
| Bethanechol |
Detrusor stimulation |
Oral, inexpensive, noninvasive |
Variable efficacy and cholinergic toxicity |
| Surgical correction |
Mechanical obstruction |
Addresses root cause |
Invasive and condition-specific |
| Neuromodulation |
Selected refractory disorders |
Longer-term treatment option |
Cost, procedural risk, patient selection |
What generic launch risks exist for bethanechol chloride?
Generic launch risk is low from a patent perspective but moderate from a supply and margin perspective.
Manufacturing and intellectual-property barriers
Manufacturing barriers may include:
- Limited API suppliers
- Low annual demand
- Small production runs
- Dose-strength inventory requirements
- Stability and dissolution controls
- Quality-system costs
- Hospital purchasing pressure
- Difficulty maintaining all strengths simultaneously
The strongest commercial moat is dependable supply. A manufacturer that can maintain 5 mg, 10 mg, 25 mg, and 50 mg tablet availability may gain procurement share even without patent protection.
Geographic coverage
Bethanechol availability is uneven across jurisdictions. Patent expiry is global in practical terms, but regulatory approvals, local manufacturers, pharmacopoeial requirements, reimbursement rules, and distribution economics determine actual access.
The United States has an established generic framework. India and other manufacturing jurisdictions may have broader supplier participation but lower realized pricing. European availability can vary by country because national authorization and reimbursement decisions are decentralized. In some markets, hospital procurement or pharmacy compounding may substitute for regular retail distribution.
What licensing deals could create value in bethanechol chloride?
A conventional license for the active ingredient would have limited value. More credible licensing opportunities would involve:
- A pediatric oral liquid
- A stable ready-to-use formulation
- Modified-release tablets
- A combination product for a defined bladder disorder
- A specialty distribution agreement
- Regional rights tied to an approved formulation
- A manufacturing or API-supply partnership
Any commercial deal would depend on formulation differentiation, regulatory exclusivity, manufacturing reliability, or distribution access. A simple license for generic bethanechol tablets would likely face low royalty capacity.
What is the investment outlook for bethanechol chloride?
Bethanechol is a defensive, low-growth generic opportunity rather than an innovation-led pharmaceutical asset. Revenue exposure is limited, but supply shortages can produce short-term pricing opportunities. The asset may suit a company with an existing generic urology portfolio, established API sourcing, and low-cost manufacturing.
The investment case is weak for:
- Standalone clinical development
- Broad indication expansion
- Branded sales infrastructure
- Patent litigation strategies
- Large-scale commercial promotion
The investment case is stronger for:
- Reliable generic supply
- Niche hospital contracting
- Specialty formulations
- Contract manufacturing
- Portfolio bundling with other urology products
Key Takeaways
- Bethanechol chloride is an established generic muscarinic agonist used mainly for nonobstructive urinary retention and bladder atony.
- No active late-stage clinical development program or major label-expansion effort is apparent.
- The active ingredient and conventional tablet formulations have no meaningful remaining patent protection.
- Orange Book and Paragraph IV risk for standard generic tablets is low.
- The market is small, fragmented, and highly sensitive to manufacturer exits and shortages.
- Revenue is likely to remain flat to modestly declining through 2030 in the base case.
- The strongest commercial opportunity is dependable supply or a differentiated pediatric, liquid, or modified-release formulation.
- Biosimilar risk does not apply because bethanechol is a small-molecule drug.
- Litigation and licensing value are limited unless tied to a new formulation, combination product, or manufacturing platform.
FAQs About Bethanechol Chloride
Is bethanechol chloride still being manufactured?
Yes. Generic bethanechol chloride products remain available in some markets, although supply can vary by dose strength, manufacturer, and distribution channel.
Is bethanechol chloride a controlled substance?
No. Bethanechol is not a federally controlled substance in the United States.
Does bethanechol chloride have generic competition?
Yes. Generic competition is established, and the reference brand does not provide a meaningful commercial barrier to generic products.
Can bethanechol chloride receive new patent protection?
The old active ingredient cannot regain composition-of-matter protection. A sponsor could potentially patent a genuinely novel formulation, delivery system, combination, manufacturing process, or narrowly defined method of use.
Is bethanechol chloride used for urinary retention after surgery?
Yes. Postoperative nonobstructive urinary retention is one of its established uses, although clinical management depends on the cause of retention and may require catheterization or treatment of obstruction.
References
-
National Library of Medicine. (n.d.). DailyMed: Bethanechol chloride tablet drug labels. U.S. National Library of Medicine.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov search results for bethanechol. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.). Bethanechol chloride prescribing information. FDA-approved product labeling.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, 45th ed. FDA Orange Book.
